Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Zhang, Xin; Wang, Xuemei; Hou, Lijian; Xu, Zheng; Liu, Yue; Wang, Xueju

doi:10.3389/fphar.2023.1130937

Cited by 4 publications

(2 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New synthetic biology approaches allow for the direct delivery of payloads by cancer-specific, natural or synthetic nanoparticles capable of targeting tumor cell surface antigens [ 48 ]. These payloads can induce regulated cell death of cancer cells directly, while simultaneous transgenic expression of immune modifiers (before the death of the same cancer cells) can exponentially activate the relevant players of the MCN in the TME [ 81 – 83 ] (Fig. 1 B).…”

Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning

confidence: 99%

Shifting the paradigm: engaging multicellular networks for cancer therapy

Hu,

Ascierto,

Cesano

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Most anti-cancer modalities are designed to directly kill cancer cells deploying mechanisms of action (MOAs) centered on the presence of a precise target on cancer cells. The efficacy of these approaches is limited because the rapidly evolving genetics of neoplasia swiftly circumvents the MOA generating therapy-resistant cancer cell clones. Other modalities engage endogenous anti-cancer mechanisms by activating the multi-cellular network (MCN) surrounding neoplastic cells in the tumor microenvironment (TME). These modalities hold a better chance of success because they activate numerous types of immune effector cells that deploy distinct cytotoxic MOAs. This in turn decreases the chance of developing treatment-resistance. Engagement of the MCN can be attained through activation of immune effector cells that in turn kill cancer cells or when direct cancer killing is complemented by the production of proinflammatory factors that secondarily recruit and activate immune effector cells. For instance, adoptive cell therapy (ACT) supplements cancer cell killing with the release of homeostatic and pro-inflammatory cytokines by the immune cells and damage associated molecular patterns (DAMPs) by dying cancer cells. The latter phenomenon, referred to as immunogenic cell death (ICD), results in an exponential escalation of anti-cancer MOAs at the tumor site. Other approaches can also induce exponential cancer killing by engaging the MCN of the TME through the release of DAMPs and additional pro-inflammatory factors by dying cancer cells. In this commentary, we will review the basic principles that support emerging paradigms likely to significantly improve the efficacy of anti-cancer therapy.

show abstract

Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning

confidence: 99%

Shifting the paradigm: engaging multicellular networks for cancer therapy

Hu,

Ascierto,

Cesano

et al. 2024

J Transl Med

View full text Add to dashboard Cite

show abstract

“…For instance, the use of anti-angiogenic agents can disrupt the blood supply to the tumor, thereby weakening its growth and survival. [ 50 ] Additionally, inhibitors that target immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, can potentially rejuvenate the immune response within the tumor microenvironment. [ 51 ] By employing these strategies, the aim is to reshape the tumor milieu, making it more conducive for immune cells to operate effectively.…”

Section: Overcoming Drug Resistance In Gi Cancer Immunotherapymentioning

confidence: 99%

Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review

Yao,

Li,

Duan

et al. 2024

Medicine

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers pose a significant challenge due to high prevalence and mortality. While advancements in detection and conventional treatments have been made, prognosis often remains poor, particularly for advanced-stage cancers. Immunotherapy has emerged as a transformative approach, leveraging the body immune system against cancer, including immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer. These modalities have shown promise, achieving sustained responses and improved survival in some patients. However, their efficacy in GI cancers is less pronounced, hindered by drug resistance mechanisms that are either intrinsic or acquired over time. This review examines the latest understanding of immunotherapy in GI cancers, focusing on ICIs, cancer vaccines, and adoptive cell transfer, along with their associated outcomes and limitations. It delves into the mechanisms behind drug resistance, including alterations in immune checkpoints, the immunosuppressive tumor microenvironment, and genetic/epigenetic changes. The role of the gut microbiome is also considered as an emerging factor in resistance. To combat drug resistance, strategies such as enhancing immune response, targeting the tumor microenvironment, and modulating resistance mechanisms are explored. The review underscores the potential of ferroptosis induction as a novel approach. Looking forward, it highlights the need for personalized immunotherapies, understanding the influence of the gut microbiome, and further exploration of ferroptosis in overcoming resistance. While challenges persist, the continuous evolution in GI cancer immunotherapy research promises innovative treatments that could significantly improve patient outcomes.

show abstract

Future Perspectives of Cancer Immunotherapy for the Treatment of Lung Cancer

Gupta,

Shetty

2024

Immunotherapy Against Lung Cancer

View full text Add to dashboard Cite

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Cited by 4 publications

References 137 publications

Shifting the paradigm: engaging multicellular networks for cancer therapy

Shifting the paradigm: engaging multicellular networks for cancer therapy

Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review

Future Perspectives of Cancer Immunotherapy for the Treatment of Lung Cancer

Contact Info

Product

Resources

About